2020
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu B, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research 2020, 26: 4186-4197. PMID: 32354698, DOI: 10.1158/1078-0432.ccr-20-0798.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerImmune checkpoint inhibitorsAnti-PD-1/PD-L1 antibodiesAdvanced non-small cell lung cancerNSCLC brain metastasesBrain metastasesPD-L1 antibodiesAnti-PD-1/PD-L1 agentsPD-1/PD-L1 blockersActive central nervous system (CNS) involvementHigh PD-L1 expressionAnti-PD-1/PD-L1 drugsCentral nervous system involvementPivotal phase III trialsActive brain metastasesCNS response ratesPD-L1 agentsPD-L1 blockersSystemic therapy combinationsNervous system involvementPD-L1 expressionPhase III trialsSubset of patientsCell lung cancerPD-L1 drugs
2019
Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti–PD-1/PD-L1 agents: Phase 2 LEAP-004 study.
Arance Fernandez A, Ascierto P, Carlino M, Daud A, Eggermont A, Hauschild A, Kluger H, Taylor M, Smith A, Chen K, Krepler C, Diede S, O'Day S. Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti–PD-1/PD-L1 agents: Phase 2 LEAP-004 study. Journal Of Clinical Oncology 2019, 37: tps9594-tps9594. DOI: 10.1200/jco.2019.37.15_suppl.tps9594.Peer-Reviewed Original ResearchPD-1/PD-L1 inhibitor therapyPD-L1 inhibitor therapyPD-1 inhibitorsRECIST v1.1Advanced melanomaLast doseInhibitor therapyAnti-PD-1/PD-L1 agentsKey secondary end pointPrimary efficacy end pointEnd pointActive autoimmune diseaseAdequate organ functionBaseline tumor samplesECOG PS 0/1Exploratory biomarker analysisNCI CTCAE v4.0PD-L1 agentsUnresectable stage IIIAntitumor activityEfficacy end pointSecondary end pointsWeeks of therapyPhase 2 trialKey inclusion criteria